The global medical and scientific communities are mourning the loss of Dr. Maura Gillison, MD, PhD, an internationally renowned physician-scientist whose groundbreaking discoveries transformed the understanding and treatment of head and neck cancer. Dr. Gillison passed away on June 21, 2026, surrounded by her family, leaving behind an extraordinary legacy of innovation, mentorship, and compassionate patient care.
Throughout her distinguished career, Dr. Gillison revolutionized the field of oncology by demonstrating that human papillomavirus (HPV), particularly HPV-16, is responsible for a distinct subset of head and neck cancers. Before her landmark research, tobacco and alcohol use were widely believed to be the primary causes of these cancers. Her pioneering work fundamentally changed the medical community’s understanding of oropharyngeal cancer and paved the way for new approaches to diagnosis, staging, treatment, and prevention.
Her discoveries established HPV-positive oropharyngeal cancer as a biologically unique disease, reshaping clinical practice worldwide. Dr. Gillison’s research further revealed that HPV status is one of the strongest predictors of patient outcomes, influencing treatment decisions and leading to less intensive therapies for many patients. Her work also strengthened global support for HPV vaccination programs for both boys and girls as an effective cancer prevention strategy.
Dr. Gillison played an instrumental role within NRG Oncology and the RTOG Foundation, where she co-chaired the landmark RTOG 0129 clinical trial alongside Dr. Kian Ang. The study identified patients with HPV-positive head and neck cancer who could safely receive less intensive treatment, reducing long-term side effects while maintaining excellent outcomes. The findings were published in the New England Journal of Medicine and became a cornerstone of modern head and neck cancer care.
She later served as Co-Principal Investigator of the NRG-RTOG 1016 trial, which demonstrated that cetuximab was inferior to cisplatin for patients with HPV-positive oropharyngeal cancer, providing critical evidence that continues to guide treatment standards around the world. Dr. Gillison also led and contributed to numerous innovative clinical trials investigating advanced therapies for patients with head and neck squamous cell carcinoma.
Beyond her scientific achievements, Dr. Gillison was admired as a devoted wife, mother, mentor, and advocate for women pursuing careers in medicine and scientific research. Colleagues remember her as fearless, brilliant, compassionate, and deeply committed to improving the lives of patients while nurturing the next generation of physician-scientists.
Tributes from fellow researchers and medical leaders have highlighted her remarkable intellect, humility, and unwavering dedication to advancing cancer care. Her discoveries have saved countless lives, influenced international treatment guidelines, and will continue benefiting patients for generations to come.
As family, friends, colleagues, and the global oncology community mourn her passing, they also celebrate the extraordinary legacy Dr. Maura Gillison leaves behind. Her groundbreaking contributions to cancer research, tireless commitment to patient care, and enduring influence on medical science ensure that her impact will be remembered for decades to come.